Market Executive Summary

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. Side effects include medullary thyroid cancer, kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient. An injection version was approved in 2017 in the United States, and in Europe, Canada, and Japan in 2018. An version which is taken by mouth was approved in 2019 in the United States. It is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. It was developed by the Danish company Novo Nordisk.

The global Semaglutide market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period 2023-2029.

The United States market for Semaglutide is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The China market for Semaglutide is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The Europe market for Semaglutide is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global key manufacturers of Semaglutide include Novo Nordisk. etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Semaglutide, the top five companies hold a share nearly %.

In terms of sales (consumption) side, this report focuses on the sales of Semaglutide by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2029.

The global Semaglutide market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Semaglutide market. These figures have been provided in terms of both revenue and sales for the period 2018-2029. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.

By Company

Novo Nordisk

By Type

Injection

Oral

By Application

Hospital

Clinic

Sales by Region

    North America

        U.S.

        Canada

    China

    APAC (excluding China)

        Japan

        South Korea

        China Taiwan

       Southeast Asia

    Europe

        Germany

        France

        U.K.

        Italy

        Russia

    Middle East, Africa, Latin America

        Brazil

        Mexico

        Turkey

        Israel

        GCC Countries

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Semaglutide in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 3: Detailed analysis of Semaglutide manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by company, by type, by application and by country, sales, and revenue for each segment.

Chapter 7: Europe by company, by type, by application and by country, sales, and revenue for each segment.

Chapter 8: China by company, by type and by application, sales, and revenue for each segment.

Chapter 9: APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.

Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Semaglutide sales, revenue, price, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: The main points and conclusions of the report.